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Abstract
The majority of patients with pancreatic carcinoma (hepaticojejunostomy) unfortunately will have palliative treatment and
palliation of symptoms is important to improve Quality of Life. The most common symptoms that require palliation are
jaundice, gastric outlet obstruction and pain. Obstructive jaundice should be treated with a biliary bypass, the optimal
palliation in relatively fit patients and endoscopic stenting is preferred in patients with short survival (36 months). To
prevent gastric outlet obstruction a prophylactic gastroenterostomy should be performed routinely during bypass surgery.
Symptomatic patients after earlier stenting of the bile duct can be treated nowadays by duodenal stenting. Pain management
is according to the progressive analgesic ladder but a (percutaneous) neurolytic celiac plexus block may be indicated.
Currently a R1 (palliative) resection is acceptable in high volume centres but so far there is a very limited role for planned
R2 palliative resections.
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Introduction
Pancreatic tumors are the fifth most common cause of
cancer-related death in the Western world [1,2]. The
incidence in the US is around 10 per 100 000 per
year. The majority of these tumors are pancreatic
adenocarcinomas and the survival is poor [14].
Despite surgical treatment with or without radio-
therapy and chemotherapy, the overall 5-year survival
is around 4% and has hardly improved during recent
decades [3]. Unfortunately the majority of patients
will present with ‘incurable’ disease due to extensive
local disease or metastases at the time of diagnosis.
There is confusion about the terminology, as the
terms ‘incurable’, ‘inoperable’, and ‘unresectable’
have a variety of interpretations. The term unresect-
able is also partly dependent on the local surgical
philosophy, for example, including a resection of the
mesenteric or portal vein, as well as the acceptance of
macroscopically nonradical resections. This surgical
philosophy is not only a country-related pattern
or ‘part of the world’-related pattern but may also
be influenced by the experience per center as well as
local tradition of surgeons. The strong relation
between outcome and mortality may play a role in
the indication for resection and acceptance of pallia-
tive resections [57]. It has even been questioned
whether cure is possible at all in patients with
pancreatic cancer [3]. There is, however, consensus
that patients who undergo resection have the best
chance for long-term survival [3,4,8].
Thus overall the majority of patients will have
palliative treatment and therefore palliation of symp-
toms will still be an important focus. The three most
important symptoms that should be treated in ad-
vanced pancreatic cancer are obstructive jaundice,
duodenal obstruction, and pain.
The decision to aim for palliative treatment can be
made at two different time points during the disease.
The first point is generally after the staging proce-
dures and a selection is made for potential curative
surgery, palliative surgery or nonsurgical (endoscopic)
palliation. A second time point for selection of a
treatment strategy is during surgical exploration and
a decision can be made for a curative resection, a
resection for optimal palliation or other surgical
procedures for palliative treatment.
Thus, accurate initial staging remains the crucial
step for the selection of surgical and nonsurgical
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(palliative) treatment. Contrast-enhanced spiral com-
puted tomography (CT), magnetic resonance imaging
(MRI), and endoscopic ultrasonography have en-
hanced the accuracy of radiological imaging, and
noninvasive staging procedures are currently first
choice [911]. Patients who are found to have a
resectable tumor at preoperative noninvasive diagnos-
tic work-up (dependent on local philosophy) should
undergo an exploratory laparotomy directly. Patients
with unresectable or incurable disease found during
exploration (1150%) are generally considered to be
best treated with surgical palliation [1214].
The current knowledge of different aspects of
surgical and endoscopic palliative treatment for
the above-mentioned symptoms (i.e. obstructive
jaundice, duodenal obstruction, and pain) will be
summarized in this review.
Obstructive jaundice
At the time of diagnosis up to 90% of patients with
pancreatic tumors present with obstructive jaundice.
More severe consequences are liver dysfunction and
eventually hepatic failure due to bile stasis and
cholangitis. Cholangitis is more frequently found in
patients with ampullary lesions than in patients with
pancreatic cancer. Relief of the obstructive jaundice
causes a dramatic increase in the quality of life of
patients and should therefore always be accomplished
[15].
Biliary drainage can be achieved nonsurgically by
placement of a biliary stent (endoscopic or percuta-
neous) or surgically by performing a biliary bypass.
The success rate for short-term relief of biliary
obstruction is comparable for both surgical and
nonsurgical biliary drainage procedures and varies
between 80 and 100%.
In the past, endoscopic biliary drainage was widely
performed using plastic (Teflon and polyethylene)
stents. Plastic stents can give rise to complications
such as migration and occlusion, reported up to 40%.
A new stent type for endoscopic treatment is the self-
expandable (covered) metallic stent; occlusion will
lead to cholangitis. Compared with plastic stents,
expandable stents have a longer patency, but cannot
be removed after placement [16,17].
Internal biliary drainage is generally preferred and
performed by a cholecystojejunostomy, choledo-
cho(hepatico)jejunostomy or choledochoduodenost-
omy [18]. In this extensive review the success rate of
cholecystojejunostomy to relieve obstructive jaundice
was lower than that for choledochojejunostomy.
A randomized controlled trial (RCT) also confirmed
that the technically more difficult choledochojejunost-
omy is preferred over a cholecystoenterostomy, due to
the lower rate of recurrent jaundice and cholangitis
and a better patency of the bypass [19].
A choledochoduodenostomy is not recommended
because it is generally thought that this drainage
procedure frequently results in recurrent jaundice
due to local tumor ingrowth into the duodenum and
the distal common bile duct.
In our institution (AMC, Amsterdam) a side-to-
side Roux-en-Y hepaticojejunostomy is performed
after removal of the gallbladder in case of detection
of advanced disease or metastases. According to the
extension of dissection and in an attempt to dissect
locally advanced disease, the common bile duct may
be transected in an early phase of the exploration and
an end-to-side bilio-enteric anastomosis is made by a
one layer running suture [20].
Results of surgical or endoscopic/percutaneous drainage
Five prospective RCTs have been performed, of
which four compared surgical biliary drainage and
endoscopic drainage [12,2124]. In the first trial by
Bornman et al. percutaneous biliary drainage was
used and no differences were found between percu-
taneous and surgical palliation [22] (Table I). The
other studies are relatively old studies and were
performed between 1988 and 1994, except for the
study by Nieveen et al. in which patients underwent a
diagnostic laparoscopy as a final staging procedure
and randomization for stent versus bypass was per-
formed after proven metastasis [12]. The studies by
Shepherd et al. [23] and Andersen et al. [21] were
both hampered by the small number of patients that
were randomized. Furthermore, the length of follow-
up in both studies is unclear and the registration of
complications and the re-admission rate are rather
limited. In the study by Smith et al. [24] 201 patients
were randomized. A higher procedure-related mortal-
ity was found after bypass compared with stenting
(14% versus 3%, respectively). Interestingly, the
30-day mortality was not significantly different (15%
versus 8%, respectively) but was still relatively high.
Major complications after bypass versus stenting were
significantly different, 29% versus 11%, respectively,
and the minor complications rates were comparable,
i.e. 29% versus 18%. The recurrence of jaundice and
cholangitis during follow-up was significantly higher
after stenting (36% versus 2%) and survival was
comparable in both groups [24]. Taylor et al. [25]
conducted a meta-analysis using the three above-
mentioned studies and concluded that more treat-
ment sessions were required after stent placement
than after surgery, with a common odds ratio
estimated to be 7.23.
The more recent randomized study by Nieveen et al.
analysed the value of a diagnostic laparoscopy in
297 patients with a periampullary carcinoma [12].
A relatively small number of patients who were found
to have uncurable disease due to metastases were
allocated to either surgical (double bypass) or
endoscopic palliation by a Wallstent. There was no
difference in procedure-related morbidity or number
of re-admitted patients between the surgically and
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endoscopically palliated patients (Table I). The mean
hospital-free survival was 164 days after surgical
palliation and 94 days after endoscopic palliation.
The survival was 192 and 116 days in the surgical
and endoscopic group, respectively (p/0.05). It must
be kept in mind, however, that this concerns a selected
group of patients who were thought to have a resectable
tumor after conventional radiological staging.
So far a few general conclusions can be drawn from
the available studies. Surgical treatment of biliary
obstruction in unresectable pancreatic cancer is asso-
ciated with higher early morbidity, longer hospital
stay, and probably higher initial mortality rate, but
long-term results are better. Endoscopic treatment is
associated with a lower initial mortality and morbidity
but more frequently leads to late biliary complications
and re-interventions due to clotting of the stent,
infection, and gastric outlet obstruction. The results
for the newest development of a stent without a lumen
are awaited [26].
Gastric outlet obstruction
Symptoms of gastric outlet obstruction (GOO) such
as nausea and vomiting are reported in 1150% of
patients with pancreatic cancer at the time of diag-
nosis [1]. For the optimal palliative treatment, it is
important to determine the origin of these symptoms.
The first cause is motility dysfunction of the stomach
and duodenum due to tumor infiltration of the celiac
nerve plexus [27] or probably dysfunction of the small
bowel due to tumor infiltration around the mesenteric
artery. The second cause of GOO is mechanical
obstruction of the duodenum due to direct tumor
ingrowth into the duodenum or secondary to com-
pression of the duodenum by a tumor in the direct
vicinity. At presentation, mechanical obstruction is
reported in around 5% of patients with pancreatic
tumours. Approximately 320% of patients with
unresectable pancreatic cancer will eventually develop
mechanical GOO [14,28].
In the patients who are found to have an unresect-
able tumor at laparotomy, a gastrojejunostomy (in
addition to a biliary bypass) can easily be performed
without substantial morbidity.
On the other hand endoscopic duodenal stenting
was recently introduced and also accepted as a
nonsurgical palliative treatment of duodenal obstruc-
tion [29,30]. In a multicenter study the success rate
after stent placement was 84% and oral intake in
patients with succesful stent placement resumed for a
median time of 146 days. So far no randomized trials
have been performed to compare endoscopic duode-
nal stenting versus surgical gastroenterostomy.
Therefore, even between surgeons there remains a
debate as to whether or not to perform a prophylactic
gastrojejunostomy.
Two recent RCTs have evaluated the role of a
prophylactic gastrojejunostomy in patients who wereT
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found to have an unresectable periampullary or
pancreatic tumour during explorative laparotomy
[14,31]. The patients in both studies received either
a prophylactic retrocolic gastrojejunostomy and a
biliary bypass (double bypass) or a biliary bypass
alone (single bypass) and also underwent a chemical
splanchnicectomy during the laparotomy. The addi-
tion of a prophylactic gastrojejunostomy did not
increase procedure-related mortality and morbidity
rates and did not extend hospital stay (Table II). None
of the patients who received a gastrojejunostomy in
the study by Lillemoe et al. [14] developed late GOO
during follow-up, compared with 19% of patients who
did not undergo a gastrojejunostomy during the initial
procedure. There was no significant difference in
survival between both groups. Van Heek et al. also
randomly assigned patients who were found to be
unresectable during exploration to either a single or a
double bypass in a multicenter trial [31]. Because the
study by Lillemoe et al. was published shortly after
the start of this study, an interim analysis was
performed after 50% (n/70) of the inclusion. Con-
cerning mortality, morbidity, survival, and hospital
stay, this study showed comparable results to the
study by Lillemoe et al. (Table II). The study by van
Heek et al. also longitudinally evaluated the quality of
life using the EORTC-C30 and Pan 26 questionnaires
and no major differences in the quality of life were
found between the two surgical treatment groups
[31]. After surgery most quality of life scores deterio-
rated temporarily and were restored to their pre-
operative levels within 4 months. This pattern of a
temporary deterioration of the different domains of
quality of life score and restoration after a few months
was recently also found in patients undergoing a
Whipple procedure and comparable with the tempor-
ary deterioration of quality of life after bypass surgery
[13]. From these trials it might be concluded that a
prophylactic gastrojejunostomy is preferable to a
biliary bypass alone, because of the significantly
reduced risk of late GOO and the low morbidity and
mortality rates. However, it has to be realized that in
these two studies endoscopic stenting of duodenal
obstruction during follow-up was not attempted and
this might influence the outcome in the near future.
Pain management
At the time of diagnosis, approximately 4080% of
patients already report pain complaints. As the disease
progresses,/90% of the patients will eventually have
to deal with moderate to severe pain. The pain of
advanced pancreatic cancer is most frequently located
in the upper abdomen (epigastric region) and the back
and is generally caused by tumor ingrowth into the
mesenteric and celiac nerve plexus.
According to the World Health Organization
(WHO) guidelines, the initial pain management
should be pharmacological, and consists of analgesics
such as nonsteroidal anti-inflammatory drugs
(NSAIDs) and oral or transdermal narcotic analgesics
[WHO 1986]. However, side effects of these drugs are
reported frequently and eventually pharmaceutical
pain management alone may not be sufficient in
patients with pancreatic carcinoma [32]. The next
step is a celiac plexus nerve block, which was first
described by Kappis in 1914 [33]. It interrupts the
innervation of the pancreas and prevents painful
stimuli from reaching the brain. Currently the celiac
plexus block can be performed percutaneously, en-
doscopically or during laparotomy.
The percutaneous route to block the celiac plexus
has been investigated extensively. It can be performed
under fluoroscopic, CT, or ultrasound guidance. In
a meta-analysis of 24 publications that included
1145 patients treated with a percutaneous neurolytic
celiac plexus block for cancer pain (63% pancreatic
cancer), 7080% of patients had a long-lasting benefit
from the procedure [34].
There are only a few RCTs on percutaneous
neurolytic celiac plexus blockade (NCPB) [3537].
Best evidence is the recent study by Wong et al. [37].
They randomly assigned 100 patients with unresect-
able pancreatic cancer to receive either NCPB or a
sham NCPB procedure. The major findings were that
NCPB, as compared with optimized analgesic ther-
apy, significantly improved pain relief in patients with
pancreatic cancer, but did not affect the quality of life
or survival. Furthermore, NCPB had no effect on
the consumption of analgesics and significantly more
patients needed a rescue NCPB in the analgesic
therapy group (10 versus 3 patients, p/0.01). These
results suggest that the application of an aggressive
Table II. Two prospectively randomized controlled trials analyzing a prophylactic gastrojejunostomy in patients who underwent a
hepaticojejunostomy for unresectable periampullary cancer.
Lillemoe et al. 1999 [14] Van Heek et al. 2003 [31]
Study Double bypass n/44 Single bypass n/43 Double bypass n/36 Single bypass n/29
Morbidity (%) 32 33 31 28
Mortality (%) 0 0 3 0
Hospital stay (days) 8.5 8 11 9
Late gastric outlet obstruction (%) 0 19 5.5 41.4
Survival (months) 8.3 8.3 7.2 8.4
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pain management protocol, regardless of NCPB, can
control pain effectively, although NCPB can provide
significantly better analgesia than optimized analgesic
therapy alone.
More recently, endoscopic ultrasound-guided fine-
needle injection therapy has been developed [38,39].
Different techniques have been described. Generally
510 ml xylocaı¨ne 1% and then 1520 ml alcohol
95% are injected at two areas of the celiac trunk.
Results from non-randomized studies showed a sig-
nificant reduction of pain in 8590% of the patients;
however, studies and follow-up are rather limited.
Endoscopic pancreatic duct stenting has also been
used successfully for relief of pain [40].
Celiac plexus block during surgery
Celiac plexus block during surgery has already been
performed for many years. Lillemoe et al. performed a
double-blinded RCT that compared a chemical
splanchnicectomy during laparotomy with alcohol
versus saline placebo [41]. Chemical splanchnicect-
omy was performed peroperatively by injection of
20 ml of either 50% alcohol or saline solution on each
side of the aorta at the level of the celiac axis.
Compared with the placebo group, alcohol injection
significantly reduced the mean pain score for surviv-
ing patients at 2, 4, and 6 months. In the alcohol
group, significantly more patients never reported pain
until death (56% versus 34%). Interestingly, actuarial
survival was improved in the subgroup of patients who
reported significant preoperative pain and underwent
a splanchnicectomy with alcohol (pB/0.0001). The
authors suggested that the difference can be caused by
the progressive physical deterioration due to persis-
tent pain, which eventually leads to impaired survival.
Another strategy to palliate pain is thoracoscopic
splanchnicectomy. This can be performed by a
bilateral thoracoscopic splanchnicectomy or a unilat-
eral left-sided thoracoscopic splanchnicectomy. Ihse
et al. performed a prospective study analyzing the
follow-up of patients with pancreatic cancer (n/23)
or chronic pancreatitis (n/21) who underwent a
bilateral thoracoscopic splanchnicectomy [42].
Within 1 week, the average pain scores reduced by
/50% and remained stable throughout the follow-up
period, which was 4 months for the patients with
pancreatic cancer. More recently Leksowski showed
adequate and consistent pain relief in 26 patients
undergoing a unilateral splanchnicectomy [43].
Radiotherapy can also be applied to reduce pan-
creatic cancer pain. However, it may take several
weeks before the relief of pain is achieved and side
effects are common. Furthermore, due to the fractio-
nated delivery of the radiotherapy, the treatment time
for these patients with a short life expectancy is
considerable. Most studies are limited due to small
patient numbers and poor pain assessment methods;
pain relief was experienced in 68% of patients, with a
median duration of 6 months to pain progression
[44,45].
Pancreaticoduodenectomy for palliation
Several reports have appeared which discussed the
indications for performing a pancreaticoduodenect-
omy (PD) as a palliative treatment option [4648].
This controversial question results from the observa-
tion in recent literature that morbidity and mortality
rates after PD are decreasing. In early reports
mortality after pancreatic resection was around 25%.
In recent reports large series from specialized centres
showed mortality rates below 5% [6,8,4952]. This
decreased mortality is partly due to improved man-
agement of severe complications [53,54] but is may
also be due to a hospital-volume effect [57,5052].
Frequently the term ‘palliative resection’ has been
used incorrectly to describe this topic. In most
patients in the above-mentioned studies the palliative
resection was regarded as a macroscopically radical
resection, which appeared to be microscopically
irradical after pathological examination (a so-called
R1 resection). Although the resection was undertaken
with a curative intention, it can be considered as
palliative. In this case the R1 resection is called
‘palliative in retrospect’. It is debatable whether these
patients should be included if the role of a palliative
resection per se is discussed, because these patients
underwent a resection with a curative intention. The
term palliative resection should therefore only be used
for R2 resections (resections with macroscopically
residual tumor). There are a few of these situations,
for example, when the tumor is found to be unresect-
able after a point of no return (e.g. transection of the
pancreatic neck), or when resection is required due to
preoperative tumor bleeding.
However, there might also be a limited role for a
planned palliative resection. Unfortunately there are
no prospective studies in which a resection was
performed or planned as a palliative procedure lead-
ing to an R2 resection, but results of the so-called R1
resection are available.
Retrospectively, two studies investigated the role of
a pancreaticoduodenectomy for palliation by compar-
ing the outcome of irradical resections to the outcome
of patients who underwent a single or double bypass
for a locally invasive tumour without metastases
[46,47]. Again, most patients underwent laparotomy
with the intention of undergoing a curative resection.
Results show that a pancreaticoduodenectomy can
be performed with similar mortality, morbidity rates,
and hospital stay, compared to a palliative bypass
(Table III). Remarkably, the survival after a palliative
resection is significantly longer than after bypass. This
difference is probably due to patient selection and the
limited compatibility of the two groups. In another
retrospective study survival was 15.8 versus 9.5
months, respectively (pB/0.01) [48]. It can be con-
Palliative surgical and endoscopic treatment of pancreatic carcinoma 373
cluded that controversy remains as to the role of a
pancreatic resection for palliation. The available data
confirm that, in the case of questionable radical
resectability, a resection can offer relatively good
palliation, so a more aggressive approach could be
advocated in patients with a doubtful resectable
tumor.
Laparoscopic palliation
Diagnostic laparoscopy has been used frequently in
the diagnostic work-up for patients with suspected
pancreatic tumors. Due to improved CT scan techni-
ques the benefit of diagnosing metastases has been
reduced to around 10% [12,55]. The use of diagnos-
tic laparoscopy has also introduced the minimally
invasive approach for subsequent palliation if metas-
tases or local ingrowth of tumors are found.
The procedures include palliation of obstructive
jaundice by cholecystojejunostomy or choledochoje-
junostomy and GOO by a gastroenterostomy.
Although a cholecystojejunostomy as a biliary
bypass is considered to be less suitable because of
the higher incidence of recurrent jaundice, this
strategy is easier and safer than a hepaticojejunost-
omy. To prevent short-term obstruction of the chole-
cystojejunostomy, the tumor status in relation to the
cystic junction anatomy should always be assessed by
performing cholangiography, otherwise a laparoscopic
common bile duct exploration and hepaticojejunost-
omy is indicated. The available data show that
the laparoscopic double bypass can be performed
safely, with acceptable morbidity and low mortality
(Table IV). However, the long-term follow-up con-
cerning recurrent jaundice and GOO is only high-
lighted briefly in these studies [5658]. As mentioned
earlier, the new endoscopic techniques including
duodenal stenting for gastric outlet obstruction [59
61] should be compared with new minimally invasive
laparoscopic approaches.
Conclusions
The most common symptoms that require palliation
in patients with pancreatic cancer are obstructive
jaundice, GOO, and pain.
To palliate obstructive jaundice, a biliary bypass
should be performed on relatively fit patients. Com-
pared with endoscopic biliary stenting, a biliary
bypass provides optimal long-term prevention of
biliary obstruction, but is associated with higher initial
morbidity. Stents are preferred in patients with a
relatively short survival (36 months).
In addition to the biliary bypass, gastric bypass
should be performed routinely to prevent GOO due to
tumor ingrowth or compression of the duodenum.
Novel techniques for palliation of GOO are being
developed, such as endoscopic duodenal stenting.
However, these techniques still have to be validated.
More than 90% of patients will have to deal with
severe pain during the course of the disease. The
initial treatment can be analgesic, but when the
disease progresses this will not be sufficient in several
cases. A neurolytic celiac plexus block can be per-
Table IV. Three cohort studies evaluating combined laparoscopic biliary and gastric bypass.
Rhodes et al. 1995 [56] Rothlin et al. 1999 [57] Kuriansky et al. 2000 [58]
Study n/16 n/14 n/12
Successful laparoscopic treatment (%) 94 100 100
Mean operating time (min) 75 129 89
Morbidity (%) 12.5 7 33
Mortality (%) 0 0 8
Mean hospital stay (days) 4 9.4 6.4
Recurrent jaundice and/or cholangitis (%) 0 NS NS
Gastric outlet obstruction (%) NS NS 17
Survival (days) 201 NS 85
NS, not stated in the article.
Table III. Studies that compared palliative resection and bypass surgery.
Reinders et al. 1995 [46] Lillemoe et al. 1996 [47] Kuhlmann et al. 2005 [48]
Study Resection n/36 Bypass n/24 Resection n/64 Bypass n/62 Resection n/80 Bypass n/90
Median tumour size (cm) 4.30 4.25 3.6 NS 2.9 3.5
Morbidity (%) 44 33 42 32 41 31
Hospital mortality (%) 3 0 1.6 1.6 0 2
2-year survival (%) 24 2 16 8 24 2
Hospital stay (days) 25 18 18 15 16 10
Chemoradiation (%) 17 17 78 48 14 44
NS, not stated in the article.
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formed percutaneously or during laparotomy. When
the tumor is found to be unresectable during explora-
tion, a plexus block is a relatively straightforward
procedure. Radiotherapy can also be applied to treat
pain, but data are limited.
So far there is a very limited role for R2 palliative
resection.
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